DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Simon A, Domanovits H, Ay C, Sengoelge G, Levy JH, Spiel AO.
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
J Thromb Haemost 2017;
15 (07) 1317-1321
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.